Strategic Initiative
Slingshot members are tracking this corporate initiative:
Zogenix (ZGNX) Makes Acquisition of Modis Therapeutics for its proprietary, late-stage investigational MT1621 targeting Thymidine Kinase 2 deficiency
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ZGNX |
|
|
Modis Therapeutics |
|
|
|
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Aug 26, 2019 Projected Implementation: Q3, 2019 Relevance Tracked Until: Q4, 2019
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Thymidine Kinase 2 Deficiency, Mt1621
